Merck KGaA, Darmstadt, Germany, Completes Acquisition of Intermolecular
- US$ 62 million acquisition to strengthen semiconductor technology offering
- Combined portfolio to accelerate materials innovation and shorten time-to-market
- Additional milestone for proposed Versum acquisition achieved
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the completion of its acquisition of Intermolecular, Inc., a California-based company for advanced materials innovation. The transaction creates a strong solutions provider in the electronic materials industry positioned to drive the development of next-generation digital devices and technologies.
“Today is a very special day for us as we successfully complete the acquisition and welcome Intermolecular to our company. For three and a half centuries, we have been dedicated to advancing science and technology for the benefit of human progress. I am glad that Intermolecular shares this spirit. Together we are well-positioned to drive and accelerate future innovations in the electronic materials industry,” said Kai Beckmann, member of the Executive Board of Merck KGaA, Darmstadt, Germany, and CEO Performance Materials.
The closing follows the satisfaction of regulatory clearances and other customary closing conditions. Upon closing, approximately 90 employees at Intermolecular’s Research & Development site in San Jose, California, USA will become part of the Performance Materials business sector of Merck KGaA, Darmstadt, Germany.
On May 6, 2019, Merck KGaA, Darmstadt, Germany, signed a definitive agreement to acquire Intermolecular through a subsidiary for US$1.20 per share in an all-cash transaction, representing an equity value of approximately US$ 62 million.
Intermolecular possesses application-specific materials expertise as well as accelerated learning and experimentation platforms with a powerful analytics infrastructure that complement the business and technology portfolio of Merck KGaA, Darmstadt, Germany. Intermolecular’s fabrication and testing capabilities allow material combinations to be tested directly within the specific target application. In comparison with conventional methods, these capabilities translate to major time reductions in the development process, dramatically accelerated learning cycles and insights into novel material systems to provide customers with unique service value.
Merck KGaA, Darmstadt, Germany, has also achieved another important milestone in its strategic ‘Bright Future’ transformation program. On September 16, 2019, Versum Materials Inc. and Merck KGaA, Darmstadt, Germany, received notice from the Committee on Foreign Investment in the United States (“CFIUS”) stating that CFIUS has completed its review of the proposed acquisition of Versum by Merck KGaA, Darmstadt, Germany, and has concluded that there are no unresolved national security concerns with respect to the transaction. The parties continue to work toward closing in the second half of 2019, subject to receipt of antitrust approval in China and the satisfaction of other customary closing conditions. On April 12, 2019, Merck KGaA, Darmstadt, Germany, signed a definitive agreement to acquire Versum Materials, one of the world's leading suppliers of innovation-driven, high-purity process chemicals, gases and equipment for semiconductor manufacturing, for US$53 per share in cash.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 52,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany, generated sales of € 14.8 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
Merck KGaA, Darmstadt, Germany will present data from a Phase II placebo-controlled randomized trial at the 2021 American Academy of Neurology (AAN) Annual Meeting.